Sector
PharmaceuticalsOpen
₹1,175Prev. Close
₹1,177.4Turnover(Lac.)
₹1,757.26Day's High
₹1,185.85Day's Low
₹1,132.152 Week's High
₹1,247.1552 Week's Low
₹318.75Book Value
₹148.42Face Value
₹1Mkt Cap (₹ Cr.)
18,261.36P/E
0EPS
1.93Divi. Yield
0.4210 Jul 2024
12:00 AM
Board Meeting
Agenda : Audited Result
29 May 2024
12:00 AM
Dividend
Dividend Amount: 5
Record Date: 02 Aug, 2024
9 Aug 2024
12:00 AM
AGM
Announcement Date: 09 Aug, 2024
This FDA audit confirms compliance with regulatory standards, enhancing the credibility of Jubilant's operations in the United States.
Jubilant Pharmova Ltd has gained a total of 126% in the last one year, and almost 75% gain since the beginning of the year.
Here are some of the stocks that may see significant price movement today: Tata Motors, Reliance Industries, IREDA, etc.
Drug company Jubilant Pharmova Ltd will acquire an 80% stake in Pierre Fabre Laboratories' Research & Development Centre in Saint Julien, France.
| Y/e 31 Mar( In .Cr) | Mar-2024 | Mar-2023 | Mar-2022 | Mar-2021 |
|---|---|---|---|---|
Equity Capital | 15.9 | 15.9 | 15.93 | 15.93 |
Preference Capital | 0 | 0 | 0 | 0 |
Reserves | 2,358.6 | 2,398.6 | 1,265.89 | 1,266.52 |
Net Worth | 2,374.5 | 2,414.5 | 1,281.82 | 1,282.45 |
Minority Interest |
| Y/e 31 Mar( In .Cr) | Mar-2021 | Mar-2020 | Mar-2018 | Mar-2017 |
|---|---|---|---|---|
Revenue | 2,709.49 | 3,139.9 | 3,306.32 | 2,491.22 |
yoy growth (%) | -13.7 | -5.03 | 32.71 | -6.2 |
Raw materials | -1,450.36 | -1,684.42 | -1,780.39 | -1,307.02 |
As % of sales | 53.52 | 53.64 | 53.84 | 52.46 |
Employee costs | -220.67 | -264.9 | -264.41 | -226.3 |
| Y/e 31 Mar( In .Cr) | Mar-2021 | Mar-2020 | Mar-2018 | Mar-2017 |
|---|---|---|---|---|
Profit before tax | 273.16 | 300.54 | 367.69 | 114.52 |
Depreciation | -99.97 | -107.39 | -82.59 | -81.12 |
Tax paid | -58.69 | 22.3 | -104.25 | -35.32 |
Working capital | -964.78 | 534.81 | -82.75 | -63.88 |
Other operating items |
| Y/e 31 Mar | Mar-2021 | Mar-2020 | Mar-2018 | Mar-2017 |
|---|---|---|---|---|
Growth matrix (%) | ||||
Revenue growth | -13.7 | -5.03 | 32.71 | -6.2 |
Op profit growth | 15.13 | -31.21 | 69.57 | 1.83 |
EBIT growth | -14.14 | -13.15 | 74.13 | 0.6 |
Net profit growth | -33.21 | 21.9 | 232.65 | 8.48 |
| Particulars (Rupees in Crores.) | Mar-2024 | Mar-2023 | Mar-2022 | Mar-2021 | Mar-2020 |
|---|---|---|---|---|---|
Gross Sales | 6,644.8 | 6,219.3 | 6,059.17 | 5,963.88 | 5,842.85 |
Excise Duty | 0 | 0 | 0 | 0 | 0 |
Net Sales | 6,644.8 | 6,219.3 | 6,059.17 | 5,963.88 | 5,842.85 |
Other Operating Income | 58.1 | 62.4 | 70.99 | 134.66 | 132.94 |
Other Income | 92.8 | 50.6 | 11.29 | 290.64 | 257.88 |
Company Name | LTP (₹) | P/E (%) | Mkt.Cap (₹Cr.) | NP Qtr (₹Cr.) | Div.Yield (%) | Sales Qtr (₹.Cr) | Book Value (₹) |
|---|---|---|---|---|---|---|---|
Sun Pharmaceuticals Industries Ltd SUNPHARMA | 1,901.95 | 162.71 | 4,52,850.48 | 237.82 | 0.72 | 4,409.74 | 98.75 |
Divis Laboratories Ltd DIVISLAB | 6,142.25 | 94.94 | 1,57,701.61 | 430 | 0.5 | 2,063 | 507.93 |
Cipla Ltd CIPLA | 1,595.75 | 32.91 | 1,30,708.75 | 1,055.94 | 0.8 | 3,752.25 | 346.39 |
Torrent Pharmaceuticals Ltd TORNTPHARM | 3,497.05 | 77.55 | 1,16,560.45 | 469 | 0.81 | 2,394 | 201.77 |
Dr Reddys Laboratories Ltd DRREDDY | 6,599.2 | 26.66 | 1,09,845.92 | 1,417.2 | 0.61 | 5,823.9 | 1,458.55 |
Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.
Chairman (Non-Executive)
Shyam S Bhartia
Co-Chairman & Non-Exe.Director
Hari S Bhartia
Non-Exec. & Independent Dir.
Vivek Mehra
Non-Exec. & Independent Dir.
SUSHIL KUMAR ROONGTA
Managing Director
Priyavrat Bhartia
Joint Managing Director
Arjun Shanker Bhartia
Non-Exec. & Independent Dir.
Arun Seth
Whole Time Director & CFO
Arvind Chokhany
Company Sec. & Compli. Officer
Naresh Kapoor
Independent Director
Shirish Gundopant Belapure
Whole-time Director
Ramakrishnan Arul
Independent Director
Harsh Mahajan
Independent Director
Shivpriya Nanda
Tel: -
Website: -
Email: -
Tel: -
Website: -
Email: -
Reports by Jubilant Pharmova Ltd
Summary
Jubilant Pharmova Limited, (Formerly known as Jubilant Life Sciences Limited), is an integrated global pharmaceutical and life sciences company engaged in Pharmaceuticals, Life Science Ingredients and Drug Discovery Solutions. The Company is engaged in pharmaceuticals, contract research and development services and proprietary novel drugs. The pharmaceuticals segment, through wholly owned subsidiary Jubilant Pharma Limited, is engaged in manufacture and supply of Active Pharmaceutical Ingredients (APIs), Solid Dosage Formulations, Radiopharmaceuticals, Allergy Therapy Products and Contract Manufacturing of Sterile Injectables and Non-Sterile Products through 6 US FDA approved manufacturing facilities in India, USA and Canada with a network of over 48 radiopharmacies in the USA. The contract research and development segment provides drug discovery and development services as well as clinical data software and service solutions. . Proprietary novel drugs segment is a patient-focused biopharmaceutical business working to address unmet medical needs in oncology and autoimmune diseases. The Company was incorporated in 21st June, 1978. The Company tapped capital market in the year 1981 by the way of its Initial Public Offering (IPO). During the year 1983, the companys commercial production of Vinyl Acetate Monomer (VAM was started to enhance the value of the company. Research & Development center of the company got recognition from Government of India in the year 1985. JLSL had in
Read More
What is the Jubilant Pharmova Ltd share price today?
The Jubilant Pharmova Ltd shares price on NATIONAL STOCK EXCHANGE (NSE) is ₹1146.35 today.
What is the Market Cap of Jubilant Pharmova Ltd?
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Jubilant Pharmova Ltd is ₹18261.36 Cr. as of 11 Oct ‘24
What is the PE and PB ratio of Jubilant Pharmova Ltd?
The PE and PB ratios of Jubilant Pharmova Ltd is 0 and 7.94 as of 11 Oct ‘24
What is the 52 Week High and Low of Jubilant Pharmova Ltd?
The 52-week high/low is the highest and lowest price at which a Jubilant Pharmova Ltd stock has traded during that given time period (similar to 1 year) and is considered as a technical indicator. The 52 week high and low of Jubilant Pharmova Ltd is ₹318.75 and ₹1247.15 as of 11 Oct ‘24
What is the CAGR of Jubilant Pharmova Ltd?
Jubilant Pharmova Ltd's CAGR for 5 Years at 23.62%, 3 Years at 23.43%, 1 Year at 179.73%, 6 Month at 81.32%, 3 Month at 62.20% and 1 Month at 15.63%.
What is the shareholding pattern of Jubilant Pharmova Ltd?
The shareholding pattern of Jubilant Pharmova Ltd is as follows:
Promoters - 50.68 %
Institutions - 23.56 %
Public - 25.18 %
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Securities Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2024, IIFL Securities Ltd. All Rights Reserved
www.indiainfoline.com is part of the IIFL Group, a leading financial services player and a diversified NBFC. The site provides comprehensive and real time information on Indian corporates, sectors, financial markets and economy. On the site we feature industry and political leaders, entrepreneurs, and trend setters. The research, personal finance and market tutorial sections are widely followed by students, academia, corporates and investors among others.
Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
Invest wise with Expert advice
